2019-2021年北京市肺结核病防治工作效果评价  

Evaluation on the effect of Tuberculosis prevention and treatment in Beijing,2019-2021

作　　者：胡艳平 贺晓新 罗萍 张红伟 李波 HU Yan-ping;HE Xiao-xin;LUO Ping;ZHANG Hong-wei;LI Bo(Beijing Center for Disease Prevention and Control,Beijing 100035,China)

机构地区：[1]北京市疾病预防控制中心,100035

出　　处：《首都公共卫生》2023年第2期96-99,共4页Capital Journal of Public Health

摘　　要：目的 分析北京市肺结核病防控工作数据,了解结核病防治体系运行情况。方法 通过中国疾病预防控制信息系统收集北京市2019年、2020年与2021年肺结核患者登记信息、肺结核患者耐药筛查和治疗转归信息。通过北京市结核病防治专项工作报表,获取结核病患者督导访视和规律服药情况。比较2021年与2019年、2020年北京市肺结核患者发现、随访、服药管理、督导访视和病原学阳性肺结核患者耐药筛查等数据的变化。结果 2021年北京市肺结核报告发病率30.7/10万,较2019年(32.2/10万)下降4.66%,较2020年(28.6/10万)上升7.34%。初诊患者查痰率由91.10%(2019年)提高到95.99%(2020年)、95.80%(2021年),差异有统计学意义(χ^(2)=235.51,P<0.001)。报告肺结核患者登记管理率由76.36%(2019年)、72.73%(2020年),上升至80.35%(2021年),差异有统计学意义(χ^(2)=104.173,P<0.001)。治疗成功率分别为94.20%、94.40%、93.81%,差异无统计学意义(χ^(2)=1.563,P=0.458)。社区管理率分别为93.53%(4 957/5 300)、97.59%(4 365/4 473)、97.52%(5 263/5 397),2021年较2019年有提高,差异有统计学意义(χ^(2)=99.865,P<0.001),与2020年基本持平(χ^(2)=0.048,P=0.827)。肺结核患者规律服药率分别由98.73%、98.80%上升至99.40%,差异有统计学意义(χ^(2)=12.080,P=0.002)。肺结核患者耐药筛查率分别为94.52%、94.92%和95.48%,差异无统计学意义(χ^(2)=1.991,P=0.370)。结论 2019-2022年北京市结核病防治服务体系运行良好,未来应继续强化保障结核病服务体系,以确保在任何情况下都能提供正常的诊疗管理服务。Objective To analyze the data of tuberculosis prevention and control in Beijing,and to understand the current running status of tuberculosis prevention and control system.Methods The registration information,drug resistance screening and treatment outcome of tuberculosis patients in Beijing in the year of 2019,2020 and 2021,were collected through Disease Control and Prevention Information System of China.Information on the tuberculosis patients’supervision visits and regular medication taking were obtained through the Beijing basic public health service project(tuberculosis patients’health management)report.The changes of discovery,follow-up examination,medication management and supervision visit of pulmonary tuberculosis patients in Beijing during the three periods were compared.Results In 2021,the detection rate of tuberculosis in Beijing was 30.7/100000,which was 4.66%lower than that in 2019(32.2/100000)and was 7.34%higher than that in 2020(28.6/100000).The sputum test rate of newly diagnosed patients increased from 91.10%(2019)to 95.99%(2020)and 95.80%(2021),with a statistically significant difference(χ^(2)=235.51,P<0.001).The registration rates of report tuberculosis patients increased from 76.36%(2019)and 72.73%(2020)to 80.35%(2021).The difference was statistically significant(χ^(2)=104.173,P<0.001).The treatment success rate of 2019,2020 and 2021 were 94.20%,94.40%and 93.81%respectively,with no statistically significant difference(χ^(2)=1.563,P=0.458).The community management rates of the years mentioned above were 93.53%(4957/5300)、97.59%(4365/4473)、97.52%(5263/5397).In 2021,there was an improvement compared to 2019,with a statistically significant difference(χ^(2)=99.865,P<0.001),which was basically the same as in 2020(χ^(2)=0.048,P=0.827).The regular medication rate of tuberculosis patients increased respectively from 98.73%、98.80%to 99.40%,the difference was statistically significant(χ^(2)=12.080,P=0.002).Finally,the drug resistance screening rate increased from 94.52%、94.92%to 95.48%

关 键 词：结核 肺 结核病防治 疾病管理 

分 类 号：R521[医药卫生—内科学]